A clinical study of plasma derived anti-COVID-19 immunoglobulin

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Aug 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Aug 2020 New trial record
10 Aug 2020 According to a Kamada media release, Kedrion is responsible for the collection of COVID-19 convalescent plasma from U.S. recovered patients and will be collecting the plasma through its plasma business unit, KEDPLASMA, at 23 FDA-approved centers across the United States.
10 Aug 2020 According to a Kamada media release, intends to conduct a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) during the current quarter and initiate the clinical program the U.S. in early 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com